Kronos Bio (KRON) Competitors $0.80 -0.04 (-4.76%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.13%) As of 04:56 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRON vs. YMAB, PLX, CKPT, TVGN, ACIU, CRGX, VYGR, AMRN, LFVN, and BTMDShould you be buying Kronos Bio stock or one of its competitors? The main competitors of Kronos Bio include Y-mAbs Therapeutics (YMAB), Protalix BioTherapeutics (PLX), Checkpoint Therapeutics (CKPT), Tevogen Bio (TVGN), AC Immune (ACIU), CARGO Therapeutics (CRGX), Voyager Therapeutics (VYGR), Amarin (AMRN), LifeVantage (LFVN), and biote (BTMD). These companies are all part of the "pharmaceutical products" industry. Kronos Bio vs. Y-mAbs Therapeutics Protalix BioTherapeutics Checkpoint Therapeutics Tevogen Bio AC Immune CARGO Therapeutics Voyager Therapeutics Amarin LifeVantage biote Kronos Bio (NASDAQ:KRON) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, community ranking, risk, media sentiment and profitability. Which has more volatility and risk, KRON or YMAB? Kronos Bio has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Which has preferable valuation and earnings, KRON or YMAB? Y-mAbs Therapeutics has higher revenue and earnings than Kronos Bio. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Kronos Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKronos Bio$9.85M4.95-$112.67M-$1.43-0.56Y-mAbs Therapeutics$87.69M2.40-$21.43M-$0.67-6.96 Is KRON or YMAB more profitable? Y-mAbs Therapeutics has a net margin of -28.22% compared to Kronos Bio's net margin of -867.66%. Y-mAbs Therapeutics' return on equity of -24.61% beat Kronos Bio's return on equity.Company Net Margins Return on Equity Return on Assets Kronos Bio-867.66% -64.55% -48.18% Y-mAbs Therapeutics -28.22%-24.61%-18.49% Do insiders & institutionals have more ownership in KRON or YMAB? 64.1% of Kronos Bio shares are held by institutional investors. Comparatively, 70.8% of Y-mAbs Therapeutics shares are held by institutional investors. 24.4% of Kronos Bio shares are held by insiders. Comparatively, 22.5% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in KRON or YMAB? Y-mAbs Therapeutics received 117 more outperform votes than Kronos Bio when rated by MarketBeat users. However, 65.63% of users gave Kronos Bio an outperform vote while only 63.30% of users gave Y-mAbs Therapeutics an outperform vote. CompanyUnderperformOutperformKronos BioOutperform Votes2165.63% Underperform Votes1134.38% Y-mAbs TherapeuticsOutperform Votes13863.30% Underperform Votes8036.70% Do analysts rate KRON or YMAB? Kronos Bio currently has a consensus target price of $1.63, indicating a potential upside of 103.13%. Y-mAbs Therapeutics has a consensus target price of $18.30, indicating a potential upside of 292.70%. Given Y-mAbs Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Kronos Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kronos Bio 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Y-mAbs Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91 Does the media prefer KRON or YMAB? In the previous week, Kronos Bio had 1 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 1 mentions for Kronos Bio and 0 mentions for Y-mAbs Therapeutics. Kronos Bio's average media sentiment score of 1.88 beat Y-mAbs Therapeutics' score of 0.00 indicating that Kronos Bio is being referred to more favorably in the media. Company Overall Sentiment Kronos Bio Very Positive Y-mAbs Therapeutics Neutral SummaryY-mAbs Therapeutics beats Kronos Bio on 12 of the 19 factors compared between the two stocks. Remove Ads Get Kronos Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRON vs. The Competition Export to ExcelMetricKronos BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.78M$6.73B$5.54B$7.49BDividend YieldN/A2.79%5.35%4.04%P/E Ratio-0.566.9923.2518.07Price / Sales4.95198.60361.2686.80Price / CashN/A65.6738.1634.64Price / Book0.295.926.493.99Net Income-$112.67M$142.37M$3.21B$247.18M7 Day Performance-3.03%-9.32%-6.42%-6.42%1 Month Performance-13.51%-10.26%-0.68%-7.44%1 Year Performance-36.51%-15.08%6.05%-4.31% Kronos Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRONKronos Bio3.6916 of 5 stars$0.80-4.8%$1.63+103.1%-36.5%$48.78M$9.85M-0.56100Short Interest ↓YMABY-mAbs Therapeutics3.25 of 5 stars$4.43-7.9%$18.30+313.1%-67.7%$200.32M$87.69M-8.20150PLXProtalix BioTherapeutics1.9962 of 5 stars$2.56-0.8%$15.00+485.9%+109.7%$199.76M$53.40M-19.69200Positive NewsCKPTCheckpoint Therapeutics2.2602 of 5 stars$4.04flat$4.33+7.3%+110.4%$197.29M$47,000.00-2.2010Earnings ReportTVGNTevogen Bio3.0528 of 5 stars$1.08-10.0%$7.10+557.4%-61.8%$189.06MN/A0.003ACIUAC Immune2.5427 of 5 stars$1.87-5.6%$12.00+541.7%-36.8%$187.77M$27.31M-4.07140Analyst ForecastShort Interest ↑News CoverageGap DownCRGXCARGO Therapeutics3.015 of 5 stars$4.07-2.6%$15.00+268.6%-80.2%$187.43MN/A-0.96116Positive NewsVYGRVoyager Therapeutics4.4599 of 5 stars$3.38-7.4%$13.97+313.2%-66.7%$186.60M$80.00M4.76100Gap DownAMRNAmarin0.7577 of 5 stars$0.45+1.8%N/A-60.1%$184.02M$228.61M-4.98360Gap DownLFVNLifeVantage3.1303 of 5 stars$14.58+1.1%$30.50+109.2%+133.9%$182.99M$212.15M26.04260Positive NewsBTMDbiote3.4583 of 5 stars$3.33-1.8%$8.00+140.2%-43.1%$182.18M$197.19M12.81194Insider TradePositive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies YMAB Competitors PLX Competitors CKPT Competitors TVGN Competitors ACIU Competitors CRGX Competitors VYGR Competitors AMRN Competitors LFVN Competitors BTMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRON) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kronos Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kronos Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KRON Stock Free KRON Stock Alerts